43 results on '"Amy L. Lightner"'
Search Results
2. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence
- Author
-
Liliana G. Bordeianou, Amy J. Thorsen, Deborah S. Keller, Alexander T. Hawkins, Craig Messick, Lucia Oliveira, Daniel L. Feingold, Amy L. Lightner, and Ian M. Paquette
- Subjects
Gastroenterology ,General Medicine - Published
- 2023
3. Redo Continent Ileostomy in Patients With IBD: Valuable Lessons Learned Over 25 Years
- Author
-
Leonardo C. Duraes, Stefan D. Holubar, Jeremy M. Lipman, Tracy L. Hull, Amy L. Lightner, Olga A. Lavryk, Arielle E. Kanters, and Scott R. Steele
- Subjects
Gastroenterology ,General Medicine - Published
- 2022
4. Leaks From the Tip of the J-pouch: Diagnosis, Management, and Long-term Pouch Survival
- Author
-
Stefan D, Holubar, Raja Kumaran, Rajamanickam, Emre, Gorgun, Amy L, Lightner, Michael A, Valente, James, Church, Tracy, Hull, and Scott R, Steele
- Subjects
Gastroenterology ,General Medicine - Abstract
The standard of care for surgical treatment of ulcerative colitis is restorative proctocolectomy with ileal J-pouch. Leaks from the tip of the J-pouch are a known complication, but there is a paucity of literature regarding this type of leak.We aimed to describe the diagnosis, management, and long-term clinical outcomes of leaks from the tip of the J-pouch at our institution.This was a retrospective study of a prospectively maintained pouch registry.This study was conducted at a quaternary IBD referral center.Patients included those with ileal J-pouches diagnosed with leaks from the tip of the J-pouch.The main measures of outcomes were pouch salvage rate, type of salvage procedures, and long-term Kaplan-Meier pouch survival.We identified 74 patients with leaks from the tip of the J-pouch. Pain (68.9%) and pelvic abscess (40.9%) were the most common presentations, whereas 10.8% of patients presented with an acute abdomen. The leak was diagnosed by imaging and/or endoscopy in 74.3% of patients but only discovered during surgical exploration in 25.6% of patients. Some 63.5% of patients were diagnosed only after loop ileostomy closure, whereas 32.4% of patients were diagnosed before ileostomy closure. The most common methods used for diagnosis were pouchoscopy (31.1%) and gastrograffin enema (28.4%). A definitive nonoperative approach was attempted in 48.6% of patients but was successful in only 10.8% of patients overall. Surgical repair was attempted in 89.2% of patients, whereas 4.5% of patients had pouch excision. Salvage operations (n = 63) included sutured or stapled repair of the tip of the J (65%), pouch excision with neo-pouch (25.4%), and pouch disconnection, repair, and reanastomosis (9.5%). Ultimately' 10 patients (13.5%) required pouch excision, yielding an overall 5-year pouch survival rate of 86.3%.This was a retrospective review; referral bias may limit the generalizability.Leaks from the tip of the J-pouch have variable clinical presentations and require a high index of suspicion. Pouch salvage surgery is required in the majority of patients and is associated with a high pouch salvage rate. See Video Abstract at http://links.lww.com/DCR/C50 .ANTECEDENTES:El estándar de atención para el tratamiento quirúrgico de la colitis ulcerosa es la proctocolectomía restauradora con bolsa ileal en J. Las fugas del extremo de la bolsa en J son una complicación conocida, pero hay escasez de literatura sobre este tipo de fuga.OBJETIVO:Describir el diagnóstico, manejo y resultados clínicos a largo plazo de las fugas del extremo de la bolsa en J en nuestra institución.DISEÑO:Estudio retrospectivo de registro de bolsa mantenido prospectivamente.ENTORNO CLINICO:Centro de referencia de enfermedad inflamatoria intestinal cuaternaria.PACIENTES:Pacientes con bolsas ileales en J diagnosticadas con fugas del extremo de la J.PRINCIPALES MEDIDAS DE VALORACIÓN:Tasa de rescate de la bolsa, tipo de procedimientos de rescate y supervivencia a largo plazo de la bolsa Kaplan-Meier.RESULTADOS:Identificamos 74 pacientes con fugas del extremo de la bolsa en J. El dolor (68,9%) y el absceso pélvico (40,9%) fueron las presentaciones más comunes, mientras que el 10,8% de los pacientes presentaron abdomen agudo. La fuga se diagnosticó por imagen y/o endoscopia en el 74,3%, pero solo se descubrió durante la exploración quirúrgica en el 25,6%. El 63,5% fueron diagnosticados solo después del cierre de la ileostomía en asa, mientras que el 32,4% lo fueron antes del cierre de la ileostomía. Los métodos más comunes utilizados para el diagnóstico fueron la endoscopia (31,1%) y el enema de gastrografín (28,4%). Se intentó un abordaje no quirúrgico definitivo en el 48,6%, pero tuvo éxito en solo el 10,8% de los pacientes en general. Se intentó la reparación quirúrgica en el 89,2% de los pacientes, mientras que en el 4,5% se realizó la escisión del reservorio. Las operaciones de rescate (n = 63) incluyeron la reparación con sutura o grapas del extremo de la J (65%), la escisión del reservorio con neo-reservorio (25,4%) y la desconexión, reparación y reanastomosis del reservorio (9,5%). Finalmente, 10 (13,5%) pacientes requirieron la escisión de la bolsa, lo que se asocio con una alta tasa de supervivencia general de la bolsa a los 5 años del 86,3%.LIMITACIONES:Revisión retrospectiva; el sesgo de referencia puede limitar la generalización.CONCLUSIONES:Las fugas del extremo de la bolsa en J tienen presentaciones clínicas variables y requieren un alto índice de sospecha. La cirugía de rescate de la bolsa se requiere en la mayoría y se asocia con una alta tasa de rescate de la bolsa. Consulte Video Resumen en http://links.lww.com/DCR/C50 . (Traducción- Dr. Ingrid Melo ).
- Published
- 2022
5. Gracilis Flap Repair for Reoperative Rectovaginal Fistula
- Author
-
Tracy L. Hull, Amy L. Lightner, and Ipek Sapci
- Subjects
Surgical repair ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Fistula ,Gastroenterology ,General Medicine ,Enema ,Anus ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Rectovaginal fistula ,Vagina ,Medicine ,Gracilis muscle ,Median body ,business - Abstract
Surgical treatment of recurrent rectovaginal fistulas is notoriously difficult. Placement of the gracilis muscle between the vagina and anus is an advanced technique used to close persistent fistulas. We have utilized this procedure for recalcitrant fistulas and hypothesized that a gracilis interposition would offer a good treatment option for patients with refractory rectovaginal fistulas, regardless of underlying etiology.The purpose of this study was to investigate healing rates of gracilis interposition in patients with refractory rectovaginal fistulas.Following institutional review board approval, a retrospective review of all adult female patients with a diagnosis of rectovaginal fistula between January 2009 and August 2020 was performed; those who underwent gracilis interposition for definitive fistula closure were included for analysis.The study was conducted at a colorectal surgery department at a tertiary center in the United States.All patients were adult females with a diagnosis of a rectovaginal fistula who underwent gracilis interposition for definitive closure.Patient demographics, etiology of rectovaginal fistula, previous surgical intervention, presence of intestinal diversion, operative details, 30-day morbidity, recurrence of fistula, and time to recurrence. Fistula closure was defined as lack of clinical symptoms following stoma closure, negative fistula detection on gastrograffin enema' and absence of an internal opening at examination under anesthesia.Twenty-two patients were included who had a median age of 43 years (range, 19-64 years) and median body mass index of 31 kg/m 2 (range, 22-51). Median time between prior attempted surgical repair and gracilis surgery was 7 months (range, 3-17). The number of previously attempted repairs were 1-2 (n = 8), 3-4 (n = 9), and4 (n = 5). The most recent attempted surgical repair was rectal advancement flap (n = 7), transperineal +/- Martius flap (n = 4), episioproctotomy (n = 3), transvaginal repair (n = 2), and other (n = 6). All patients had fecal diversion at the time of gracilis surgery. Thirty-day postoperative surgical site infection at the graft/donor site was 32% (n = 7). At a median follow-up of 22 months (range 2-62), fistula closure was 59% (n = 13). Gracilis interposition was successful in all inflammatory bowel disease patients.The study was limited by its retrospective nature.Gracilis interposition is an effective operative technique for reoperative rectovaginal fistula closure. Patients should be counseled regarding the possibility of graft/donor site infection. See Video Abstract at http://links.lww.com/DCR/B763 .ANTECEDENTES:El tratamiento quirúrgico de las fístulas rectovaginales recurrentes es muy difícil. La colocación del músculo gracilis entre la vagina y el ano es una técnica avanzada que se utiliza para cerrar las fístulas persistentes. Hemos utilizado este procedimiento para las fístulas recalcitrantes y planteamos la hipótesis de que una interposición del gracilis ofrecería una buena opción de tratamiento para pacientes con fístulas rectovaginales refractarias, independientemente de la etiología subyacente.OBJETIVO:Investigar las tasas de curación de la interposición del gracilis en pacientes con fístulas rectovaginales refractarias.DISEÑO:Tras la aprobación de la junta de revisión institucional, se realizó una revisión retrospectiva de todas las pacientes adultas con un diagnóstico de fístula rectovaginal entre enero de 2009 y agosto de 2020; los que se sometieron a interposición de gracilis para el cierre definitivo de la fístula se incluyeron para el análisis.AJUSTE:Departamento de cirugía colorrectal de un centro terciario en Estados Unidos.PACIENTES:Todas las pacientes adultas con diagnóstico de fístula rectovaginal que se sometieron a interposición de gracilis para cierre definitivo.PRINCIPALES MEDIDAS DE RESULTADO:datos demográficos del paciente, etiología de la fístula rectovaginal, intervención quirúrgica previa, presencia de derivación intestinal, detalles quirúrgicos, morbilidad a los 30 días, recurrencia de la fístula y tiempo hasta la recurrencia. El cierre de la fístula se definió como la ausencia de síntomas clínicos después del cierre del estoma, la detección negativa de la fístula en el enema de gastrograffin y la ausencia de una abertura interna en el examen bajo anestesia.RESULTADOS:Se incluyeron 22 pacientes que tenían una mediana de edad de 43 años (rango 19-64 años) y una mediana de índice de masa corporal de 31 kg / m2 (rango 22-51). La mediana de tiempo entre el intento previo de reparación quirúrgica y la cirugía del gracilis fue de 7 meses (rango 3-17). El número de reparaciones previamente intentadas fue: 1-2 (n = 8), 3-4 (n = 9), y4 (n = 5). El intento de reparación quirúrgica más reciente fue el colgajo de avance rectal (n = 7), el colgajo transperineal +/- Martius (n = 4), la episioproctotomía (n = 3), la reparación transvaginal (n = 2) y otros (n = 6). Todos los pacientes tenían derivación fecal en el momento de la cirugía gracilis. La infección del sitio quirúrgico posoperatorio a los 30 días en el sitio del injerto / donante fue del 32% (n = 7). Con una mediana de seguimiento de 22 meses (rango 2-62), el cierre de la fístula fue del 59% (n = 13). La interposición de Gracilis fue exitosa en todos los pacientes con enfermedad inflamatoria intestinal.LIMITACIONES:Carácter retrospectivo de los datos.CONCLUSIONES:La interposición de Gracilis es una técnica quirúrgica eficaz para el cierre reoperatorio de la fístula rectovaginal. Se debe asesorar a los pacientes sobre la posibilidad de infección del sitio del injerto / donante. Consulte Video Resumen en http://links.lww.com/DCR/B763 . (Traducción-Dr. Ingrid Melo ).
- Published
- 2022
6. Salvage Surgery: An Effective Therapy in the Management of Ileoanal Pouch Prolapse
- Author
-
Ana Otero-Piñeiro, Marianna Maspero, Stefan D. Holubar, Amy L. Lightner, Scott R. Steele, Tracy Hull, and Rupert B. Turnbull
- Subjects
Gastroenterology ,General Medicine - Published
- 2023
7. Venous Thromboembolism in Patients Admitted for IBD: An Enterprise-Wide Experience of 86,000 Hospital Encounters
- Author
-
Amy L. Lightner, Bradford Sklow, Benjamin Click, Miguel Regueiro, John J. McMichael, Xue Jia, Prashansha Vaidya, Conor P. Delaney, Benjamin Cohen, Steven D. Wexner, Scott R. Steele, and Stefan D. Holubar
- Subjects
Gastroenterology ,General Medicine - Published
- 2022
8. Small Bowel Crohn’s Disease Recurrence is Common After Total Proctocolectomy for Crohn’s Colitis
- Author
-
Nicholas Smith, Ipek Sapci, Amy L. Lightner, Benjamin H. Click, Miguel Regueiro, Tracy L. Hull, and Robert H Hollis
- Subjects
Male ,Reoperation ,medicine.medical_specialty ,Crohn's colitis ,medicine.medical_treatment ,Aftercare ,Disease ,Risk Assessment ,Gastroenterology ,Ileostomy ,Postoperative Complications ,Crohn Disease ,Recurrence ,Risk Factors ,Total Proctocolectomy ,Median follow-up ,Internal medicine ,Outcome Assessment, Health Care ,medicine ,Humans ,In patient ,Crohn's disease ,business.industry ,Proctocolectomy, Restorative ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,digestive system diseases ,Biological Therapy ,Female ,business ,Needs Assessment - Abstract
Surgical intervention for Crohn's disease involving the colon is often a total proctocolectomy with end ileostomy. There are limited data regarding postoperative small bowel recurrence rates in the recent era.The purpose of this study was to determine the rate of small bowel Crohn's disease recurrence following total proctocolectomy and secondarily define risk factors for disease recurrence.This was a retrospective cohort study.The study was conducted at four hospitals within a single healthcare system.Patients were those with Crohn's disease undergoing total proctocolectomy with end ileostomy between 2009-2019.Main outcome measures were clinical, endoscopic, radiographic, and/or surgical Crohn's disease recurrence.In total, 193 patients were included with a median follow-up of 1.8 years (IQR 0.4-4.6). Overall, 74.6% (n = 144) of patients had been previously exposed to biologic therapy, and 51.3% (n = 99) had a history of small bowel Crohn's disease. Postoperatively, 14.5% (n = 28) of patients received biologic therapy. Crohn's disease recurrence occurred in 23.3% (n = 45) of patients with an estimated median 5-year recurrence rate of 40.8% (95% CI' 30.2-51.4). Surgical recurrence occurred in 8.8% (n = 17) of patients with an estimated median 5-year recurrence rate of 16.9% (95% CI' 8.5-25.3). On multivariable analysis, prior small bowel surgery for Crohn's disease (HR 2.61; 95% CI' 1.42-4.81) and Crohn's diagnosis at age18 years (HR 2.56; 95% CI' 1.40-4.71) were associated with Crohn's recurrence. In patients without prior small bowel Crohn's disease, 14.9% (n = 14) had Crohn's recurrence with an estimated 5-year overall recurrence rate of 31.1% (95% CI' 13.3-45.3) and 5-year surgical recurrence rate of 5.7% (95% CI' 0.0-12.0).The study was limited by its retrospective design and lack of consistent follow-up on all patients.Greater than one third of patients who underwent total proctocolectomy for Crohn's disease were estimated to have small bowel Crohn's recurrence at 5 years after surgery. Patients with a history of small bowel surgery for Crohn's and diagnosis at any early age may benefit from more intensive postoperative surveillance and consideration for early medical prophylaxis. See Video Abstract at http://links.lww.com/DCR/B762.ANTECEDENTES:La cirugia para la enfermedad de Crohn que involucra el colon es a menudo una proctocolectomía total con ileostomía terminal. Hay datos limitados con respecto a las tasas de recurrencia posoperatoria de la enfermedad de Crohn del intestino delgado en la actualidad.OBJETIVO:Buscamos determinar la tasa de recurrencia de la enfermedad de Crohn del intestino delgado después de la proctocolectomía total y, en segundo lugar, definir los factores de riesgo de recurrencia de la enfermedad.DISEÑO:Estudio de cohorte retrospectivo.ENTORNO CLINICO:Cuatro hospitales de un mismo sistema sanitario.PACIENTES:Pacientes con enfermedad de Crohn sometidos a proctocolectomía total con ileostomía terminal entre 2009-2019.PRINCIPALES MEDIDAS DE VALORACIÓN:Recurrencia clínica, endoscópica, radiográfica y / o quirúrgica de la enfermedad de Crohn.RESULTADOS:Se incluyeron 193 pacientes con un seguimiento promedio de 1,8 años (IQR 0,4-4,6). El 74,6% (n = 144) de los pacientes habían recibido previamente terapia biológica y el 51,3% (n = 99) tenían antecedentes de enfermedad de Crohn del intestino delgado. Después de la operación, el 14,5% (n = 28) de los pacientes recibieron terapia biológica. La recurrencia de la enfermedad de Crohn ocurrió en el 23,3% (n = 45) de los pacientes con una tasa de recurrencia media estimada a los 5 años del 40,8% (IC del 95%: 30,2-51,4). La recidiva quirúrgica se produjo en el 8,8% (n = 17) de los pacientes con una tasa de recidiva media estimada a los 5 años del 16,9% (IC del 95%: 8,5-25,3). En el análisis multivariable, la cirugía previa del intestino delgado para la enfermedad de Crohn (HR 2,61, IC del 95%: 1,42-4,81) y el diagnóstico de Crohn a la edad18 (HR 2,56, IC del 95%: 1,40-4,71) se asociaron con la recurrencia de Crohn. En pacientes sin enfermedad previa de Crohn del intestino delgado, el 14,9% (n = 14) tuvo recurrencia de Crohn con una tasa de recurrencia general estimada a 5 años del 31,1% (IC del 95%: 13,3-45,3) y una tasa de recurrencia quirúrgica a 5 años del 5,7% (IC del 95%: 0,0-12,0).LIMITACIONES:Diseño retrospectivo, falta de seguimiento constante de todos los pacientes.CONCLUSIONES:Se estimó que más de un tercio de los pacientes que se sometieron a proctocolectomía total tenían recurrencia de Crohn del intestino delgado a los 5 años después de la cirugía. Los pacientes con antecedentes de cirugía por enfermedad de Crohn del intestino delgado y diagnóstico a una edad temprana pueden beneficiarse de una vigilancia posoperatoria más intensiva y la consideración de una profilaxis médica temprana. Consulte Video Resumen en http://links.lww.com/DCR/B762. (Traducción- Dr. Ingrid Melo).
- Published
- 2022
9. Redo Ileocolic Resection is Not an Independent Risk Factor for Anastomotic Leak in Recurrent Crohn’s Disease
- Author
-
Songsoo Yang, Christopher Prien, Xue Jia, Tracy Hull, David Liska, Scott R. Steele, Amy L. Lightner, Michael Valente, and Stefan D. Holubar
- Subjects
Gastroenterology ,General Medicine - Published
- 2023
10. Mesenteric Excision and Exclusion for Ileocolic Crohn’s Disease: Feasibility and Safety of an Innovative, Combined Surgical Approach With Extended Mesenteric Excision and Kono-S Anastomosis
- Author
-
Rebecca L. Gunter, Tracy L. Hull, Benjamin H. Click, Amy L. Lightner, Jean-Paul Achkar, Scott R. Steele, Stefan D. Holubar, Miguel Regueiro, Jeremy M. Lipman, and Florian Rieder
- Subjects
Adult ,Male ,Reoperation ,medicine.medical_specialty ,Fistula ,Colon ,Operative Time ,Constriction, Pathologic ,Anastomosis ,Postoperative Complications ,Crohn Disease ,Ileum ,Recurrence ,medicine ,Humans ,Mesentery ,Retrospective Studies ,Biological Products ,Crohn's disease ,Surgical approach ,Sutures ,business.industry ,Anastomosis, Surgical ,Gastroenterology ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Surgery ,Feasibility Studies ,Female ,Laparoscopy ,Safety ,business - Abstract
Ileocolic resection for Crohn's disease traditionally does not include a high ligation of the ileocolic pedicle, and most commonly is performed with a stapled side-to-side ileocolic anastomosis. The mesentery has recently been implicated in the pathophysiology of Crohn's disease. Two techniques have been developed and are associated with reduced postoperative recurrence: the Kono-S anastomosis that excludes diseased mesentery and extended mesenteric excision that resects diseased mesentery. We aimed to assess the technical feasibility and safety of a novel combination of techniques: mesenteric excision and exclusion.This initial report is a single-center descriptive study of consecutive adults who underwent mesenteric excision and exclusion for primary or recurrent ileocolic Crohn's disease from September 2020 to June 2021. Medication exposure and endoscopic balloon dilation before surgery were recorded. Phenotype was classified using the Montreal Classification. Thirty-day outcomes were reported. A video of the mesenteric excision and exclusion including the Kono-S anastomosis is presented.Twenty-two patients with ileocolic Crohn's disease underwent mesenteric excision and exclusion: 100% had strictures, 59% had fistulas, 81% were on biologics, and 27% had previous ileocolic resection(s). Seventy-two percent underwent laparoscopic procedures, a mesenteric defect was closed in 86%, omental flaps were fashioned in 77%, and 3 patients were diverted. Median operative time was 175 minutes. Median postoperative stay was 4 days. At 30 days, there were 2 readmissions for reintervention: 1 seton placement and 1 percutaneous drainage of a sterile collection. There were no cases of intra-abdominal sepsis or anastomotic leak.Mesenteric excision and exclusion represents an innovative, progressive, and promising approach that appears to be highly feasible and safe. Further study is warranted to determine if mesenteric excision and exclusion is associated with reduced postoperative recurrence of ileocolic Crohn's disease.
- Published
- 2021
11. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis
- Author
-
Bradley R. Davis, Ian M. Paquette, Uma Mahadevan, Kurt G. Davis, Amy L. Lightner, Vitaliy Poylin, Wolfgang B. Gaertner, Jon D. Vogel, Samir A. Shah, Sunanda V. Kane, Scott R. Steele, Stefan D. Holubar, Rectal Surgeons, and Daniel L. Feingold
- Subjects
Male ,medicine.medical_specialty ,MEDLINE ,Pouchitis ,Postoperative Complications ,medicine ,Humans ,Intestinal Mucosa ,Surgeons ,Management of ulcerative colitis ,Ileostomy ,business.industry ,General surgery ,Proctocolectomy, Restorative ,Gastroenterology ,Venous Thromboembolism ,General Medicine ,medicine.disease ,United States ,Clinical Practice ,Practice Guidelines as Topic ,Colitis, Ulcerative ,Female ,Quality-Adjusted Life Years ,business ,Colorectal Surgery - Published
- 2021
12. Management of Isolated Anal Strictures in Crohn’s Disease
- Author
-
Benjamin Click, Takayuki Yamamoto, Amy L. Lightner, Paulo Gustavo Kotze, and Antonino Spinelli
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Constriction, Pathologic ,Disease ,03 medical and health sciences ,Ileostomy ,0302 clinical medicine ,Crohn Disease ,medicine ,Humans ,Retrospective Studies ,Anus Diseases ,Crohn's disease ,business.industry ,Proctocolectomy ,General surgery ,Proctocolectomy, Restorative ,Gastroenterology ,Disease Management ,Endoscopy ,Retrospective cohort study ,General Medicine ,Anal canal ,medicine.disease ,Dilatation ,Symptomatic relief ,Biological Therapy ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Quality of Life ,Female ,030211 gastroenterology & hepatology ,business ,Anal stricture - Abstract
Background Anorectal stricturing is a particularly morbid manifestation of Crohn's disease resulting in a diminished quality of life related to pain, incontinence, and recurrent operative interventions. Objective To determine the role of medical therapy, endoscopic dilation, and surgical intervention for the treatment of isolated anorectal stricturing. Data sources An organized search of MEDLINE, PubMed, EMBASE, Scopus, and the Cochrane Database of Collected Reviews was performed from January 1, 1990 through May 1, 2020. Study selection Full text papers which included management of isolated anorectal strictures in the setting of Crohn's disease. Intervention(s) Medical and surgical management. Main outcome measures Symptomatic relief, need for proctocolectomy. Results Our search identified a total of 553 papers; after exclusion based on title (n = 430) and abstract (n = 47), 76 underwent full text review with 65 relevant to the management of anorectal strictures. A summary of the retrospective reports suggests that medical therapy can help control luminal inflammation, but fibrosis may ultimately set in resulting in a need for endoscopic or surgical intervention. Surgical options are limited in the anal canal due to inflammation and ulceration and concomitant perianal fistulizing disease. While fecal diversion can provide symptomatic relief, successful restoration of intestinal continuity remains uncommon and most patients ultimately undergo a total proctocolectomy with end ileostomy. Limitations Limited literature published, all retrospective in nature. Conclusions Despite significant advances in medical and surgical therapy in Crohn's disease over the last decades, there is clearly an unmet need in the management of anorectal strictures in Crohn's disease.
- Published
- 2020
13. Perianal Crohn’s Disease
- Author
-
Amy L. Lightner
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Fistula ,Anal Canal ,Colonoscopy ,Rectum ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,Ileum ,Incision and drainage ,medicine ,Humans ,Rectal Fistula ,Infusions, Intravenous ,Abscess ,Ulcer ,Proctitis ,medicine.diagnostic_test ,business.industry ,Perianal Abscess ,Gastroenterology ,Antibodies, Monoclonal ,General Medicine ,Anal canal ,medicine.disease ,Magnetic Resonance Imaging ,Surgery ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Drainage ,030211 gastroenterology & hepatology ,business - Abstract
CASE SUMMARY A 22-year-old man presents to your office with a perianal abscess and occasional mild crampy abdominal pain. You take him to the operating room for an examination under anesthesia (EUA) with incision and drainage of the abscess and note a transphincteric fistula tract through which you place a seton and 2 large skin tags. The anal canal and rectum are without ulceration, but there are mild proctitis and nonprolapsing internal hemorrhoids. Because of a concern for Crohn's disease (CD), he undergoes magnetic resonance enterography and colonoscopy. The magnetic resonance enterography shows inflammation in 20 cm of the distal terminal ileum, and colonoscopy reveals approximately 10 ulcers
- Published
- 2020
14. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn’s Disease
- Author
-
Samir A. Shah, Uma Mahadevan, Ian M. Paquette, Jon D. Vogel, Sunanda V. Kane, Scott R. Steele, Joseph C. Carmichael, Amy L. Lightner, Daniel L. Feingold, and Deborah S. Keller
- Subjects
medicine.medical_specialty ,MEDLINE ,Constriction, Pathologic ,Severity of Illness Index ,Management of Crohn's disease ,Crohn Disease ,Severity of illness ,medicine ,Humans ,Disease management (health) ,Intensive care medicine ,Immunosuppression Therapy ,Inflammation ,Surgeons ,Ileostomy ,business.industry ,Gastroenterology ,Antibodies, Monoclonal ,Disease Management ,General Medicine ,medicine.disease ,Dilatation ,United States ,Clinical Practice ,Practice Guidelines as Topic ,business ,Colorectal Surgery - Published
- 2020
15. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Left-Sided Colonic Diverticulitis
- Author
-
Luca Stocchi, Sang W. Lee, Daniel L. Feingold, Karin M. Hardiman, Jason F. Hall, Rectal Surgeons, Ian M. Paquette, Scott R. Steele, and Amy L. Lightner
- Subjects
medicine.medical_specialty ,business.industry ,General surgery ,Gastroenterology ,MEDLINE ,General Medicine ,Diverticulitis ,medicine.disease ,Left sided ,Clinical Practice ,Medicine ,Rifaximina ,Observational Studies as Topic ,Disease management (health) ,business - Published
- 2020
16. Do Patients With Inflammatory Bowel Disease Have a Higher Postoperative Risk of Venous Thromboembolism or Do They Undergo More High-risk Operations?
- Author
-
Amy L. Lightner, Katherine A. Bews, Elizabeth B. Habermann, Kevin T. Behm, Nicholas P. McKenna, and Kellie L. Mathis
- Subjects
Adult ,Male ,medicine.medical_specialty ,Logistic regression ,Malignancy ,Inflammatory bowel disease ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Digestive System Surgical Procedures ,Aged ,business.industry ,Venous Thromboembolism ,Middle Aged ,Clostridium difficile ,Inflammatory Bowel Diseases ,equipment and supplies ,medicine.disease ,Ulcerative colitis ,United States ,Colorectal surgery ,030220 oncology & carcinogenesis ,Diverticular disease ,Female ,030211 gastroenterology & hepatology ,Surgery ,business ,Abdominal surgery - Abstract
Objective To determine the relative or combined effects of Crohn disease (CD) and ulcerative colitis (UC) and the operation performed on postoperative venous thromboembolism (VTE) to better guide recommendations on extended VTE prophylaxis. Summary background data There is growing evidence to suggest patients with inflammatory bowel disease have an increased risk of postoperative VTE, but prior studies have not accounted for the operation performed nor acknowledged differences between CD and UC. Methods The American College of Surgeons National Surgical Quality Improvement Project database from 2005 to 2016 was queried for patients with a diagnosis of CD, UC, malignancy, or benign disease (diverticular disease, Clostridium difficile) undergoing major abdominal surgery. Operations with a VTE rate >3% were designated high risk. Operation-specific univariate and multivariable logistic regression analyses were conducted. Results A total of 231,718 operations were analyzed with 4426 patients experiencing a VTE (1.9%). The overall rate of VTE ranged widely based on the operation performed from 0.7% for enterostomy closure to 5.3% for open subtotal colectomy. Seven operations met our threshold of 3% to be considered high risk. For each operation, postoperative VTE rates were similar regardless of diagnostic indication when performed in the elective setting. However, when performed emergently, the same operations had significantly higher VTE rates. Compared with the malignancy and benign disease groups, neither CD nor UC was associated with increased odds of VTE after any operation. Conclusions Postoperative VTE risk varies widely by the operation performed, and a diagnostic indication of CD or UC does not play a role. Extended duration VTE prophylaxis should be considered in all patients undergoing high-risk operations, regardless of their underlying diagnosis.
- Published
- 2020
17. Hemorrhoidectomy and Excision of Skin Tags in IBD: Harbinger of Doom or Simply a Disease Running Its Course?
- Author
-
Elizabeth B. Habermann, Amy L. Lightner, Kellie L. Mathis, and Nicholas P. McKenna
- Subjects
Adult ,Hemorrhoidectomy ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Dermatologic Surgical Procedures ,Interventional management ,Anastomosis ,Hemorrhoids ,Rubber band ligation ,Inflammatory bowel disease ,Time-to-Treatment ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,medicine ,Humans ,Colitis ,Retrospective Studies ,Skin ,Gynecology ,Proctectomy ,business.industry ,Perianal Abscess ,Gastroenterology ,General Medicine ,Middle Aged ,medicine.disease ,Ulcerative colitis ,030220 oncology & carcinogenesis ,Colitis, Ulcerative ,Female ,030211 gastroenterology & hepatology ,business - Abstract
Background Controversy in performing hemorrhoidectomy and anal skin tag excision in patients with IBD stems from dated reports of nonhealing wounds resulting in proctectomy. Objective This study aimed to determine the safety of interventional management of hemorrhoids or anal skin tags in patients with Crohn's disease or ulcerative colitis. Design This study is a retrospective review of patient records from 2000 to 2017. Setting The patient records were retrieved from a multistate health system. Patients Adult patients with IBD undergoing interventional management of hemorrhoids or skin tags were included. Main outcome measure The primary outcome measured was the long-term requirement of proctectomy. Results Ninety-seven patients (n = 49 Crohn's disease, 48 ulcerative colitis) underwent interventional management of hemorrhoids or anal skin tags (n =35 rubber band ligation, 27 anal skin tag excision, 21 hemorrhoidectomy, 14 excision/incision of thrombosed hemorrhoid). Thirty-day complications were observed in 5 patients (n = 4 urinary retention, 1 perianal abscess). Five patients with Crohn's disease eventually required proctectomy at a median of 7 years after skin tag excision (range, 6 months to 10 years), but none were secondary to impaired wound healing. Two patients with ulcerative colitis who had previously undergone IPAA were subsequently diagnosed with Crohn's disease of the pouch after skin tag excision. No other long-term complications were seen in patients with ulcerative colitis. Limitations The study's retrospective design does not allow identification of patients with IBD who underwent only medical management of their hemorrhoids. There is also selection bias in which patients were selected for interventional management of their disease. Conclusions The requirement for proctectomy after hemorrhoidectomy/skin tag excision appears to be secondary to the natural disease course of perianal Crohn's disease rather than perianal intervention. Selective hemorrhoidectomy and skin tag excision in patients with well-controlled luminal disease should be considered. See Video Abstract at http://links.lww.com/DCR/B55. HEMORROIDECTOMIA ASOCIADA A LA EXCISION DE PLICOMAS EN CASOS DE ENFERMEDAD INFLAMATORIA INTESTINAL: ?ANUNCIO DE FATALIDAD O SIMPLEMENTE EVOLUCION NATURAL DE LA ENFERMEDAD?: Esta controvertida la realizacion de una hemorroidectomia asociada a la excision de plicomas ano-cutaneos en pacientes con enfermedad inflamatoria intestinal, asi lo han demostrado informes detallados sobre la no cicatrisacion de las heridas conllevando a una proctectomia.Determinar los margenes de seguridad en casos de tratamiento instrumental de hemorroides asociadas a la excision de plicomas ano-cutaneos en pacientes portadores de colitis ulcerosa o enfermedad de Crohn.Revision retrospectiva de historias clinicas de pacientes entre 2000 y 2017.Servicio Multiestatal de Salud.Adultos con enfermedad inflamatoria intestinal sometidos a tratamiento instrumental de hemorroides asociado a la excision de plicomas ano-cutaneos.Requisitos a largo plazo para una proctectomia.Noventa y siete pacientes (49 con enfermedad de Crohn, 48 con colitis ulcerosa) se sometieron a un tratamiento instrumental de hemorroides asociada a la excision de plicomas ano-cutaneos (35 ligadura con bandas elasticas, 27 excision de plicomas ano-cutaneos, 21 hemorroidectomias, 14 excisiones / incisiones de hemorroides trombosadas) Se observaron complicaciones a los 30 dias en cinco pacientes (4 con retencion urinaria, 1 absceso perianal). Cinco pacientes con enfermedad de Crohn requirieron proctectomia en una media de 7 anos despues de la excision de los plicomas ano-cutaneos (rango, 6 meses a 10 anos), pero ninguno fue secundario a la mala cicatrizacion de la herida. Dos pacientes con colitis ulcerosa que previamente se habian sometido a una anastomosis colo-anal protegia por ilestomia fueron diagnosticados posteriormente con enfermedad de Crohn localizada en la ostomia despues de la excision de plicomas ano-cutaneos. No se observaron complicaciones a largo plazo en pacientes con colitis ulcerosa.El diseno retrospectivo del estudio no permite la identificacion de pacientes con enfermedad inflamatoria intestinal que se sometieron unicamente al tratamiento medico de las hemorroides. Tambien existe un sesgo de seleccion de pacientes escogidos para tratamiento instrumental de la enfermedad hemorroidaria.El requisito de proctectomia despues de la hemorroidectomia / excision de plicomas anocutaneos parece ser secundario al curso de la enfermedad natural de la enfermedad de Crohn perianal en el sitio de la intervencion perianal. Se debe considerar la hemorroidectomia selectiva y la excision de plicomas ano-cutaneos solo en pacientes con enfermedad endoluminal controlada. Vea el video del resumen en http://links.lww.com/DCR/B55.
- Published
- 2019
18. S0695 Appropriateness of Medical and Surgical Treatments in Patients With Chronic Inflammation of the Ileal Pouch: A RAND Panel Approach
- Author
-
Miles P. Sparrow, Brian Bressler, Corey A. Siegel, Adam Chiefetz, Patricia Kozuch, Shane M. Devlin, Leonard Baidoo, Thomas A. Ullman, Gilaad G. Kaplan, Krisztina Gecse, Gaurav Syal, Gil Y. Melmed, Fernando Velayos, Laura E. Raffals, Amy L. Lightner, Peter M. Irving, Phillip Fleshner, and Jennifer Jones
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,medicine ,In patient ,Inflammation ,Pouch ,medicine.symptom ,business ,Surgery - Published
- 2020
19. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn’s Disease: Are There Differences in the Safety Profiles?
- Author
-
Laura E. Raffals, Amy L. Lightner, Maile E. Parker, Nicholas P. McKenna, William S. Harmsen, Ahmad Alsughayer, Edward V. Loftus, and Kekoa Taparra
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anti-Inflammatory Agents ,Antibodies, Monoclonal, Humanized ,Interleukin-23 ,Vedolizumab ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Crohn Disease ,Internal medicine ,Ustekinumab ,Humans ,Medicine ,Colectomy ,Biological Products ,Crohn's disease ,Tumor Necrosis Factor-alpha ,business.industry ,Gastroenterology ,Follow up studies ,General Medicine ,medicine.disease ,Interleukin-12 ,United States ,Outcome and Process Assessment, Health Care ,030220 oncology & carcinogenesis ,Preoperative Period ,Intraabdominal Infections ,Female ,030211 gastroenterology & hepatology ,Abdominal operations ,Drug Monitoring ,business ,Follow-Up Studies ,medicine.drug - Abstract
The evidence regarding the association of preoperative biologic exposure and postoperative outcomes remains controversial for both antitumor necrosis factor agents and vedolizumab and largely unknown for ustekinumab.The purpose of this study was to determine differences in the rates of 30-day postoperative overall infectious complications and intra-abdominal septic complications among the 3 classes of biologic therapies as compared with no biologic therapy.This was a retrospective review.The study was conducted at an IBD referral center.Adult patients with Crohn's disease who received an antitumor necrosis factor, vedolizumab, ustekinumab, or no biologic therapy within 12 weeks of a major abdominal operation between May 20, 2014, and December 31, 2017, were included.Thirty-day overall postoperative infectious complications and intra-abdominal septic complications were measured.A total of 712 patients with Crohn's disease were included; 272 patients were exposed to an antitumor necrosis factor agents, 127 to vedolizumab, 38 to ustekinumab, and 275 to no biologic therapy within the 12 weeks before an abdominal operation. Patients exposed to a biologic were more likely to be taking a concurrent immunomodulator, but there was no difference in concurrent corticosteroid usage. The particular class of biologic was not independently associated with total overall infectious complications. Vedolizumab was associated with an increased rate of intra-abdominal sepsis on univariate analysis but not on multivariable analysis. Combination immunosuppression was associated with both an increased rate of overall postoperative infectious complications and intra-abdominal sepsis.The study was limited by its retrospective design and single-center data.The overall rate of total infectious complications or intra-abdominal septic complications was not increased based on preoperative exposure to a particular class of biologic. Rates increased with combination immunosuppression of biologic therapy with corticosteroids and previous abdominal resection. See Video Abstract at http://links.lww.com/DCR/B24. BIOLÓGICOS Y COMPLICACIONES POSTOPERATORIAS DE 30 DÍAS DESPUÉS DE LAS OPERACIONES ABDOMINALES PARA LA ENFERMEDAD DE CROHN: ¿EXISTEN DIFERENCIAS EN LOS PERFILES DE SEGURIDAD?:: La evidencia sobre la asociación de la exposición biológica preoperatoria y los resultados postoperatorios sigue siendo controvertida controversial tanto para los agentes del factor de necrosis tumoral (anti-TNF) como para el vedolizumab, y en gran parte desconocida para el ustekinumab.Determinar las diferencias en las tasas de complicaciones infecciosas generales postoperatorias de 30 días y complicaciones sépticas intraabdominales entre las tres clases de terapias biológicas en comparación con ninguna terapia biológica.Revisión retrospectiva.centro de referencia de la enfermedad inflamatoria intestinal.Pacientes adultos con enfermedad de Crohn que recibieron un factor de necrosis antitumoral, vedolizumab, ustekinumab o ningún tratamiento biológico dentro de las 12 semanas de una operación abdominal mayor entre el 5/20/2014 y el 12/31/2017.Complicaciones infecciosas postoperatorias generales de 30 días, complicaciones sépticas intraabdominales.Se incluyeron setecientos doce pacientes con enfermedad de Crohn; 272 pacientes fueron expuestos a un anti-TNF, 127 a vedolizumab, 38 a ustekinumab y 275 a ninguna terapia biológica dentro de las 12 semanas previas a una operación abdominal. Los pacientes expuestos a un producto biológico tenían más probabilidades de tomar un inmunomodulador concurrente, pero no hubo diferencias en el uso simultáneo de corticosteroides. La clase particular de productos biológicos no se asoció de forma independiente con las complicaciones infecciosas totales. Vedolizumab se asoció con una mayor tasa de sepsis intraabdominal en el análisis univariable, pero no en el análisis multivariable. La inmunosupresión combinada se asoció tanto con una mayor tasa de complicaciones infecciosas postoperatorias generales como con sepsis intraabdominal.Diseño retrospectivo, datos de centro único.La tasa general de complicaciones infecciosas totales o complicaciones sépticas intraabdominales no aumentó en función de la exposición preoperatoria a una clase particular de productos biológicos. Las tasas aumentaron con la combinación de inmunosupresión de la terapia biológica con corticosteroides y resección abdominal previa. Vea el Resumen del Video en http://links.lww.com/DCR/B24.
- Published
- 2019
20. Does Metabolic Syndrome Increase the Risk of Postoperative Complications in Patients Undergoing Colorectal Cancer Surgery?
- Author
-
Kellie L. Mathis, Omair A. Shariq, Kristine T. Hanson, Scott R. Kelley, Nicholas P. McKenna, Amy L. Lightner, Elizabeth B. Habermann, and Eric J. Dozois
- Subjects
Adult ,Male ,Reoperation ,medicine.medical_specialty ,Databases, Factual ,Operative Time ,MEDLINE ,Patient Readmission ,Diabetes Complications ,Text mining ,Risk Factors ,Internal medicine ,Colorectal cancer surgery ,Surgical Wound Dehiscence ,medicine ,Humans ,Surgical Wound Infection ,In patient ,Colectomy ,Aged ,Retrospective Studies ,Aged, 80 and over ,Metabolic Syndrome ,business.industry ,Gastroenterology ,Retrospective cohort study ,General Medicine ,Length of Stay ,Middle Aged ,medicine.disease ,United States ,Elective Surgical Procedures ,Operative time ,Female ,Kidney Diseases ,Abdominal operations ,Metabolic syndrome ,Colorectal Neoplasms ,business - Abstract
Metabolic syndrome is associated with poorer postoperative outcomes after various abdominal operations. However, the impact of metabolic syndrome on outcomes after colorectal cancer surgery remains poorly described.The purpose of this study was to determine the association between metabolic syndrome and short-term postoperative outcomes in patients undergoing elective colorectal cancer surgery.This was a retrospective cohort study.This study used a national multicenter database.Adult patients who underwent elective colectomy for colorectal cancer from 2010 to 2016 were identified in the American College of Surgeons National Surgical Quality Improvement Program database.Thirty-day postoperative mortality and morbidity, unplanned reoperation, unplanned readmission, operative time, and length of stay were measured.A total of 91,566 patients were analyzed; 7603 (8.3%) had metabolic syndrome. On unadjusted analysis, metabolic syndrome was associated with an increased risk of 30-day overall morbidity, pulmonary complications, renal complications, septic complications, cardiac complications, wound complications, blood transfusion, longer length of stay, and unplanned readmissions. On multivariable analysis, metabolic syndrome remained significantly associated with renal complications (OR = 1.44 (95% CI, 1.29-1.60)), superficial surgical site infection (OR = 1.46 (95% CI, 1.32-1.60)), deep surgical site infection (OR = 1.40 (95% CI, 1.15-1.70)), wound dehiscence (OR = 1.47 (95% CI, 1.20-1.80)), and unplanned readmissions (HR = 1.24 (95% CI, 1.15-1.34)). The risks of overall morbidity, cardiac and septic complications, and prolonged length of stay for laparoscopic procedures were significantly associated with diabetes mellitus rather than metabolic syndrome as a composite entity.This study was limited by its retrospective design and inability to analyze outcomes beyond 30 days.Patients with metabolic syndrome undergoing elective surgery for colorectal cancer have an increased risk of 30-day postoperative renal complications, wound complications, and unplanned hospital readmissions. A multidisciplinary approach involving lifestyle modifications and pharmacologic interventions to improve the components of metabolic syndrome should be implemented preoperatively for these patients. See Video Abstract at http://links.lww.com/DCR/A909.
- Published
- 2019
21. Early Results of a Phase I Trial Using an Adipose-Derived Mesenchymal Stem Cell-Coated Fistula Plug for the Treatment of Transsphincteric Cryptoglandular Fistulas
- Author
-
Greg W. Butler, Jessica Friton, Eric J. Dozois, Heidi K. Chua, Allan B. Dietz, Kellie L. Mathis, Amy L. Lightner, Scott R. Kelley, William A. Faubion, and Joel G. Fletcher
- Subjects
Adult ,Male ,medicine.medical_specialty ,Fistula ,Treatment outcome ,Anal Canal ,Adipose tissue ,Mesenchymal Stem Cell Transplantation ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Rectal Fistula ,Medicine ,Surgical approach ,business.industry ,Mesenchymal stem cell ,Gastroenterology ,Mesenchymal Stem Cells ,General Medicine ,Middle Aged ,Anal canal ,Surgical Instruments ,medicine.disease ,Surgery ,Treatment Outcome ,medicine.anatomical_structure ,Early results ,030220 oncology & carcinogenesis ,Feasibility Studies ,Female ,030211 gastroenterology & hepatology ,business - Abstract
Management of transsphincteric cryptoglandular fistulas remains a challenging problem and the optimal surgical approach remains elusive. Mesenchymal stem cells, increasingly being utilized for perianal Crohn's disease, offer a novel therapy to treat cryptoglandular fistulas.This study aimed to determine safety and feasibility of using an autologous mesenchymal stem cell-coated fistula plug in patients with transsphincteric cryptoglandular fistulas.This study is a phase I clinical trial.This study was conducted at a tertiary academic medical center.Adult (18 years) male and female patients with transsphincteric cryptoglandular fistulas were selected.The primary outcomes measured were the safety, feasibility, and efficacy of a mesenchymal stem cell-coated fistula plug in patients with transsphincteric fistulas.Fifteen patients (8 women, mean age 39.8 years) with a single-tract transsphincteric fistula received a mesenchymal stem cell-loaded fistula plug and were followed for 6 months. Duration of disease at the time of study enrollment was a median of 3.0 years (range, 1-13 years) with a median of 3.5 (range, 1-20) prior surgical interventions. Adverse events included 1 plug extrusion, 1 abdominal wall seroma, 3 perianal abscesses requiring drainage, and 1 patient with perianal cellulitis. There were no serious adverse events. At 6 months, 3 patients had complete clinical healing, 8 had partial healing, and 4 patients showed no clinical improvement. Radiographic improvement was seen in 11 of 15 patients.This study was limited by the small cohort and short follow-up.Autologous mesenchymal stem cell-coated fistula plug treatment of transsphincteric cryptoglandular fistulas was safe and feasible and resulted in complete or partial healing in a majority of patients. See Video Abstract at http://links.lww.com/DCR/A897.
- Published
- 2019
22. Congress Report from the 13th Annual Scientific Meeting of the European Society of Coloproctology
- Author
-
Richard R. W. Brady, Antonino Spinelli, and Amy L. Lightner
- Subjects
medicine.medical_specialty ,business.industry ,General surgery ,Gastroenterology ,MEDLINE ,Medicine ,General Medicine ,business ,Colorectal surgery - Published
- 2019
23. Intra-abdominal Sepsis After Ileocolic Resection in Crohn’s Disease: The Role of Combination Immunosuppression
- Author
-
Amy E. Glasgow, Amy L. Lightner, Eric J. Dozois, Elizabeth B. Habermann, and Nicholas P. McKenna
- Subjects
Adult ,Male ,Reoperation ,medicine.medical_specialty ,Abdominal Abscess ,Adolescent ,medicine.drug_class ,medicine.medical_treatment ,Anastomotic Leak ,Disease ,030230 surgery ,Gastroenterology ,Sepsis ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Crohn Disease ,Ileum ,Risk Factors ,Internal medicine ,medicine ,Humans ,Young adult ,Colectomy ,Aged ,Aged, 80 and over ,Univariate analysis ,Crohn's disease ,business.industry ,Immunosuppression ,General Medicine ,Middle Aged ,medicine.disease ,Corticosteroid ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,business ,Immunosuppressive Agents - Abstract
BACKGROUND Intra-abdominal sepsis complicates
- Published
- 2018
24. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection
- Author
-
Marylise Boutros, Rectal Surgeons, Daniel L. Feingold, Ian M. Paquette, Alexander T. Hawkins, Anuradha R. Bhama, Vitaliy Poylin, Amy L. Lightner, and Sahil Khanna
- Subjects
Clinical Practice ,medicine.medical_specialty ,business.industry ,General surgery ,Gastroenterology ,MEDLINE ,Medicine ,General Medicine ,business ,Clostridioides - Published
- 2021
25. S712 Late Postoperative Crohn's Disease Recurrence Is Common and Differs by Baseline Inflammation
- Author
-
Edward L. Barnes, Amy L. Lightner, Jessica Philpott, Salam P. Bachour, Jordan E. Axelrad, Taha Qazi, Benjamin H. Click, Jean-Paul Achkar, Ravi S. Shah, Florian Rieder, Stefan D. Holubar, Miguel Regueiro, Bret A. Lashner, and Benjamin L. Cohen
- Subjects
medicine.medical_specialty ,Crohn's disease ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Inflammation ,medicine.symptom ,Baseline (configuration management) ,medicine.disease ,business - Published
- 2021
26. S699 Isolated Anastomotic Lesions Do Not Increase Risk for Severe Endoscopic Disease Progression in Postoperative Crohn’s Disease
- Author
-
Florian Rieder, Jordan E. Axelrad, Benjamin H. Click, Taha Qazi, Ruishen Lyu, Jean-Paul Achkar, Amy L. Lightner, Jessica Philpott, Ravi S. Shah, Benjamin L. Cohen, Miguel Regueiro, Salam P. Bachour, Bret A. Lashner, Stefan D. Holubar, and Edward L. Barnes
- Subjects
medicine.medical_specialty ,Crohn's disease ,Hepatology ,business.industry ,Internal medicine ,Disease progression ,Gastroenterology ,Medicine ,Anastomosis ,business ,medicine.disease - Published
- 2021
27. S743 Histologic Activity Does Not Predict Future Recurrence in Postoperative Crohn’s Disease
- Author
-
Florian Rieder, Benjamin H. Click, Jordan E. Axelrad, Edward L. Barnes, Miguel Regueiro, Salam P. Bachour, Stefan D. Holubar, Amy L. Lightner, Benjamin L. Cohen, and Ravi S. Shah
- Subjects
medicine.medical_specialty ,Crohn's disease ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,Medicine ,business ,medicine.disease - Published
- 2021
28. Robotic Platform for an IPAA
- Author
-
Amy L. Lightner, Scott R. Kelley, and David W. Larson
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Colonic Pouches ,Familial adenomatous polyposis ,03 medical and health sciences ,0302 clinical medicine ,Robotic Surgical Procedures ,Humans ,Medicine ,In patient ,Colitis ,Colectomy ,business.industry ,Proctocolectomy ,General surgery ,Proctocolectomy, Restorative ,Rectum ,Gastroenterology ,General Medicine ,medicine.disease ,Ulcerative colitis ,Adenomatous Polyposis Coli ,030220 oncology & carcinogenesis ,Colitis, Ulcerative ,Laparoscopy ,030211 gastroenterology & hepatology ,business - Abstract
An IPAA is the preferred operative approach for restoration of intestinal continuity in patients with ulcerative colitis and familial adenomatous polyposis. As minimally invasive approaches have become more widely adopted, their use in IPAA has also become increasingly commonplace. Laparoscopy has the same limitations during the proctectomy portion as seen in operations for rectal cancer, including dissection in the mid-to-lower rectum attributed to angles created by bony confines of the deep pelvis and lack of visibility when constructing the anastomosis. Robotic surgery provides improved 3-dimensional and high-definition visualization of the pelvis and multiple degrees of freedom, which greatly enhance performance during the proctectomy and construction of the anastomosis.In the setting of a previous subtotal colectomy, the ileostomy site is taken down and stapled across. A 15-mm balloon trocar is placed in the site to achieve insufflation, and the robotic ports are placed horizontally just above the umbilicus. The lateral mesenteric attachments are mobilized laparoscopically, then the J-pouch is constructed through the ostomy site. The J-pouch is placed back into the abdomen with the anvil in place, and the proctectomy is performed after docking the robot. The rectum is stapled with the robotic stapler and exteriorized from the ileostomy site, and the anastomosis is constructed under direct robotic visualization.In addition to the potential ergonomic advantages, the maneuverability and visualization in the pelvis during the proctectomy and construction of the anastomosis are reported by many surgeons to be improved as compared with laparoscopy, especially in male or obese patients.A robotic approach during the proctectomy and IPAA offers significant advantages to a laparoscopic approach, expanding our armamentarium of minimally invasive surgical techniques to IPAA.
- Published
- 2018
29. Perioperative Management of Biologic and Immunosuppressive Medications in Patients With Crohn’s Disease
- Author
-
Amy L. Lightner
- Subjects
medicine.medical_specialty ,MEDLINE ,Inflammation ,Disease ,Antibodies, Monoclonal, Humanized ,Drug Administration Schedule ,Perioperative Care ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Pharmacotherapy ,Crohn Disease ,Weight loss ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Biological Products ,Crohn's disease ,biology ,business.industry ,Gastroenterology ,General Medicine ,medicine.disease ,Monoclonal ,biology.protein ,Drug Therapy, Combination ,030211 gastroenterology & hepatology ,medicine.symptom ,Antibody ,business ,Immunosuppressive Agents - Abstract
CASE SUMMARY:A 23-year-old man with a 7-year history of Crohn’s disease presents with a 20-cm segment of terminal ileal inflammation with an associated 12-cm stricture. The patient describes obstructive-like symptoms and a recent 20-pound weight loss. He has previously lost response to both inflixim
- Published
- 2018
30. S713 Changing Biologic Mechanism After Detection of Endoscopic Postoperative Recurrence Promotes Endoscopic Remission
- Author
-
Bret A. Lashner, Ravi S. Shah, Benjamin H. Click, Jordan E. Axelrad, Amy L. Lightner, Jean-Paul Achkar, Jessica Philpott, Ruishen Lyu, Edward L. Barnes, Stefan D. Holubar, Taha Qazi, Miguel Regueiro, Salam P. Bachour, Benjamin L. Cohen, and Florian Rieder
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Mechanism (biology) ,Gastroenterology ,medicine ,business ,Surgery - Published
- 2021
31. S0732 Perioperative Safety of Tofacitinib in Surgical Inflammatory Bowel Disease Patients
- Author
-
Karen Zaghiyan, Janindra Warusavitarne, Francesco Maria Carrano, Antonino Spinelli, Phillip Fleshner, Prashansha Vaidya, Kapil Sahnan, Stefan D. Holubar, and Amy L. Lightner
- Subjects
medicine.medical_specialty ,Tofacitinib ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Perioperative ,medicine.disease ,business ,Inflammatory bowel disease - Published
- 2020
32. S0826 Preoperative Vedolizumab, Ustekinumab, or Anti-Tumor Necrosis Factor Use Is Not Associated with Postoperative Complications in Crohn’s Disease Patients Undergoing Ileocolic Resection
- Author
-
Amy L. Lightner, Miguel Regueiro, Jessica Philpott, Stefan D. Holubar, Taha Qazi, Jean Paul Achkar, Tracy L. Hull, Florian Rieder, Benjamin L. Cohen, Ravi S. Shah, Benjamin H. Click, Xue Jia, and Salam P. Bachour
- Subjects
medicine.medical_specialty ,Crohn's disease ,Hepatology ,business.industry ,Gastroenterology ,medicine.disease ,Vedolizumab ,Ileocolic resection ,Internal medicine ,Ustekinumab ,medicine ,Anti tumor necrosis factor ,business ,medicine.drug - Published
- 2020
33. S0825 Prior Surgical History Is the Strongest Risk Factor for Postoperative Crohn’s Disease Recurrence: A Guideline-Based Risk-Stratified Analysis
- Author
-
Benjamin H. Click, Salam P. Bachour, David Hudesman, Stefan D. Holubar, Florian Rieder, Benjamin L. Cohen, Ravi S. Shah, Takahiro I. Nakamura, Jordan E. Axelrad, Miguel Regueiro, and Amy L. Lightner
- Subjects
Stratified analysis ,Crohn's disease ,medicine.medical_specialty ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Surgical history ,Guideline ,Risk factor ,medicine.disease ,business - Published
- 2020
34. S0771 Management Approach to Iatrogenic Perforation During Colonoscopy in Crohn’s Disease Has Poor Consensus Among Gastroenterologists
- Author
-
Vinayak Shenoy, Arun Swaminath, Andrew Anh Nguyen, Amy L. Lightner, Laura Durbin, and Manasi Agrawal
- Subjects
Crohn's disease ,medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,business.industry ,General surgery ,Perforation (oil well) ,Gastroenterology ,Medicine ,Colonoscopy ,Approaches of management ,business ,medicine.disease - Published
- 2020
35. P107 Evolution of Imaging in the Preoperative Assessment of Patients Undergoing Ileal Pouch Surgery
- Author
-
Trevor Wood, Karen Zaghiyan, Amy L. Lightner, and Phillip Fleshner
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,Pouch surgery ,Medicine ,business ,Surgery - Published
- 2019
36. Report From Advances in Inflammatory Bowel Diseases 2018: An Update
- Author
-
Scott A. Strong, Paulo Gustavo Kotze, Feza H. Remzi, Jean Ashburn, Amy L. Lightner, and Phillip Fleshner
- Subjects
medicine.medical_specialty ,business.industry ,Gastroenterology ,Medicine ,Inflammatory Bowel Diseases ,General Medicine ,business ,Intensive care medicine - Published
- 2019
37. Human Papilloma Virus and Anal Squamous Cell Cancer in IBD: Is It Time to Update Our Practice Parameters?
- Author
-
Amy L. Lightner
- Subjects
Oncology ,Human papilloma virus ,medicine.medical_specialty ,biology ,business.industry ,Gastroenterology ,MEDLINE ,Inflammatory Bowel Diseases ,General Medicine ,biology.organism_classification ,medicine.disease ,Anus neoplasms ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Carcinoma ,030212 general & internal medicine ,Papillomaviridae ,Anal squamous cell cancer ,business - Published
- 2017
38. Impact of Sex on Short-Term Complications and Long-Term Functional Outcomes after Ileal Pouch Anal Anastomosis
- Author
-
Kellie L. Mathis, Eric J. Dozois, Nicholas P. McKenna, and Amy L. Lightner
- Subjects
medicine.medical_specialty ,business.industry ,medicine ,Surgery ,business ,Ileal Pouch Anal Anastomosis ,Term (time) - Published
- 2017
39. Infectious Complications in Liver Transplant Patients Exposed to Vedolizumab for the Treatment of Inflammatory Bowel Disease
- Author
-
Chung Sang Tse, Laura E. Raffals, Amy L. Lightner, and Edward V. Loftus
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Transplant patient ,medicine.disease ,business ,Inflammatory bowel disease ,Vedolizumab ,medicine.drug - Published
- 2017
40. Diagnosis and Surgical Management of Enterovesical Fistulas in Crohn’s Disease in the Biologic Era: A Multi-Institutional Analysis
- Author
-
Amy L. Lightner, Elizabeth B. Habermann, Kellie L. Mathis, and Nicholas P. McKenna
- Subjects
medicine.medical_specialty ,Crohn's disease ,business.industry ,General surgery ,medicine ,Institutional analysis ,Surgery ,medicine.disease ,business - Published
- 2018
41. Importance of Considering Portomesenteric Vein Thrombosis and Operation in the Risk of Venous Thromboembolism After Colorectal Surgery
- Author
-
Amy L. Lightner and Nicholas P. McKenna
- Subjects
medicine.medical_specialty ,business.industry ,Gastroenterology ,General Medicine ,medicine.disease ,Colorectal surgery ,Mesenteric Vein ,Surgery ,Vein thrombosis ,03 medical and health sciences ,Venous thrombosis ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,030211 gastroenterology & hepatology ,business ,Venous thromboembolism - Published
- 2018
42. Staging of Urgent Surgical Intervention for Severe Acute Refractory Inflammatory Bowel Disease (IBD) Colitis: Role of Rescue Ileostomy
- Author
-
Daniel W. Hommes, Terri Getzug, Bennett E. Roth, Jonathan Sack, Jennifer M. Choi, Amy L. Lightner, and Christina Ha
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine.disease ,Inflammatory bowel disease ,Gastroenterology ,Ileostomy ,Refractory ,Internal medicine ,Intervention (counseling) ,medicine ,Surgery ,Colitis ,business - Published
- 2015
43. Incidence of Pouchitis and Pouch Outcomes in Patients With Familial Adenomatous Polyposis Following Ileal Pouch-anal Anastomosis
- Author
-
Laura E. Raffals, Amy L. Lightner, Felicity Enders, Richard S. Pendegraft, Lisa A. Boardman, and Kevin P. Quinn
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Incidence (epidemiology) ,Gastroenterology ,Pouchitis ,medicine.disease ,Familial adenomatous polyposis ,Ileal Pouch Anal Anastomosis ,Internal medicine ,medicine ,In patient ,Pouch ,business - Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.